Loading...
XASXOPT
Market cap558mUSD
Dec 23, Last price  
0.73AUD
1D
2.84%
1Q
0.00%
Jan 2017
-14.20%
Name

Opthea Ltd

Chart & Performance

D1W1MN
XASX:OPT chart
P/E
P/S
4,464.64
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
20.91%
Rev. gr., 5y
2.08%
Revenues
125k
-22.65%
10,104016,21113,7770000582,414746,029445,175251,53057,535107,378112,49759,06168,61390,683161,163124,666
Net income
-220m
L+3.95%
12,570,34209,502,444000-11,733,97300-3,768,700-4,088,258-4,735,411-4,670,385-13,096,528-14,953,894-11,080,783-45,344,496-92,817,371-211,880,680-220,242,105
CFO
-161m
L-10.20%
0027,943,275000-10,070,15000-4,174,307-5,026,656-2,678,813-4,559,180-15,448,408-11,913,151-5,689,620-45,546,167-71,334,952-179,303,893-161,015,354
Dividend
Feb 04, 20050.15 AUD/sh
Earnings
Feb 26, 2025

Profile

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
IPO date
Apr 09, 1985
Employees
5
Domiciled in
AU
Incorporated in
AU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
125
-22.65%
161
77.72%
91
32.17%
Cost of revenue
191,815
223,710
95,192
Unusual Expense (Income)
NOPBT
(191,690)
(223,549)
(95,101)
NOPBT Margin
Operating Taxes
(9,412)
(8,810)
(6,299)
Tax Rate
NOPAT
(182,278)
(214,739)
(88,802)
Net income
(220,242)
3.95%
(211,881)
128.28%
(92,817)
104.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
158,818
81,815
256
BB yield
-568.80%
-31.68%
-0.70%
Debt
Debt current
93
97
Long-term debt
141,648
211
Deferred revenue
Other long-term liabilities
58,991
128,740
28
Net debt
(30,731)
(133,679)
(44,631)
Cash flow
Cash from operating activities
(161,015)
(179,304)
(71,335)
CAPEX
(33)
(33)
(17)
Cash from investing activities
(33)
(33)
(17)
Cash from financing activities
243,729
248,696
172
FCF
(182,107)
(211,778)
(75,017)
Balance
Cash
172,471
133,987
44,631
Long term investments
Excess cash
172,465
133,979
44,627
Stockholders' equity
(75,810)
(8,793)
47,977
Invested Capital
200,639
138,263
3,335
ROIC
ROCE
EV
Common stock shares outstanding
79,775
469,557
46,618
Price
0.35
-36.36%
0.55
-30.16%
0.79
-41.01%
Market cap
27,921
-89.19%
258,256
603.48%
36,711
-35.28%
EV
(2,809)
124,577
(7,920)
EBITDA
(191,587)
(223,399)
(95,023)
EV/EBITDA
0.01
0.08
Interest
30,263
20,014
Interest/NOPBT